PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
12635495-0	2002	KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line.	KE 758	0-6	tumor necrosis factor	Homo sapiens	93-120
11841839-0	2002	Effects of a new anti-rheumatic drug KE-298 and its active metabolite: KE-758 on secretion of thioredoxin and on the level of intracellular glutathione in human monocytes and T cells.	KE 758	71-77	thioredoxin	Homo sapiens	94-105
11841839-4	2002	KE-298 (10-100 microg/ml) and KE-758 (10-100 microg/ml) as well as a high concentration of NAC (10mM) dose-dependently inhibited the secretion of TRX by THP-1 and Jurkat cells.	KE 758	30-36	thioredoxin	Homo sapiens	146-149
11841839-4	2002	KE-298 (10-100 microg/ml) and KE-758 (10-100 microg/ml) as well as a high concentration of NAC (10mM) dose-dependently inhibited the secretion of TRX by THP-1 and Jurkat cells.	KE 758	30-36	GLI family zinc finger 2	Homo sapiens	153-158
12635495-10	2002	Thus, KE-758 inhibits both TNF-alpha and IL-1 beta production and its antirheumatic profile is apparently distinct from that of D-penicillamine, bucillamine and auranofin.	KE 758	6-12	tumor necrosis factor	Homo sapiens	27-36
12635495-10	2002	Thus, KE-758 inhibits both TNF-alpha and IL-1 beta production and its antirheumatic profile is apparently distinct from that of D-penicillamine, bucillamine and auranofin.	KE 758	6-12	interleukin 1 beta	Homo sapiens	41-50
12635495-0	2002	KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line.	KE 758	0-6	interleukin 1 beta	Homo sapiens	125-143
12635495-0	2002	KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line.	KE 758	0-6	GLI family zinc finger 2	Homo sapiens	147-152
12635495-6	2002	KE-758 and auranofin but not D-penicillamine and bucillamine significantly suppressed both TNF-alpha and IL-1 beta.	KE 758	0-6	tumor necrosis factor	Homo sapiens	91-100
12635495-6	2002	KE-758 and auranofin but not D-penicillamine and bucillamine significantly suppressed both TNF-alpha and IL-1 beta.	KE 758	0-6	interleukin 1 beta	Homo sapiens	105-114
12635495-8	2002	Reverse transcriptase-polymerase chain reaction analysis revealed that the suppressive effect of KE-758 is based on the inhibition of messenger ribonucleic acid expression of TNF-alpha and IL-1 beta.	KE 758	97-103	tumor necrosis factor	Homo sapiens	175-184
12635495-8	2002	Reverse transcriptase-polymerase chain reaction analysis revealed that the suppressive effect of KE-758 is based on the inhibition of messenger ribonucleic acid expression of TNF-alpha and IL-1 beta.	KE 758	97-103	interleukin 1 beta	Homo sapiens	189-198
8839631-3	1996	The authors compared effects of KE-758 and KE-298 on inflammatory cytokine production from human peripheral blood mononuclear cells and human umbilical vein endothelial cells (HUVEC), interleukin-1 (IL-1)-induced thymocyte proliferation (LAF) activity, adjuvant-induced arthritis in rats and lymphocyte transformation test in mice.	KE 758	32-38	interleukin 1 alpha	Homo sapiens	184-203
11409114-7	2001	RESULTS: KE-298 and KE-758 suppressed NO production by LPS activated RAW264.7 cells by inhibiting iNOS gene expression.	KE 758	20-26	nitric oxide synthase 2, inducible	Mus musculus	98-102
11409114-9	2001	LPS induced IFN-beta and IRF-1 gene expression were markedly suppressed by KE-758.	KE 758	75-81	interferon beta 1	Rattus norvegicus	12-20
11409114-9	2001	LPS induced IFN-beta and IRF-1 gene expression were markedly suppressed by KE-758.	KE 758	75-81	interferon regulatory factor 1	Rattus norvegicus	25-30
11409114-10	2001	In rats with adjuvant induced arthritis, enhanced NO and iNOS production by cultured peritoneal cells and the development of arthritis were suppressed by KE-758.	KE 758	154-160	nitric oxide synthase 2	Rattus norvegicus	57-61
11409114-11	2001	CONCLUSION: KE-758 suppressed LPS induced iNOS gene expression by murine macrophage cells by inhibiting IFN-beta/IRF-1 expression.	KE 758	12-18	nitric oxide synthase 2, inducible	Mus musculus	42-46
11409114-11	2001	CONCLUSION: KE-758 suppressed LPS induced iNOS gene expression by murine macrophage cells by inhibiting IFN-beta/IRF-1 expression.	KE 758	12-18	interferon beta 1, fibroblast	Mus musculus	104-112
11409114-11	2001	CONCLUSION: KE-758 suppressed LPS induced iNOS gene expression by murine macrophage cells by inhibiting IFN-beta/IRF-1 expression.	KE 758	12-18	interferon regulatory factor 1	Mus musculus	113-118
11409114-12	2001	The potential of KE-758 to inhibit iNOS production might partly explain its efficacy on adjuvant induced arthritis in rats.	KE 758	17-23	nitric oxide synthase 2	Rattus norvegicus	35-39
11379039-10	2001	Meanwhile, lipopolysaccharide (LPS) or LPS plus interferon-gamma (IFN-gamma) induced NO production by RAW264.7 cells were suppressed by KE-758 and auranofin but not by D-penicillamine and bucillamine.	KE 758	136-142	interferon gamma	Mus musculus	48-75